Estradiol increases ER-negative breast cancer metastasis in an experimental model

Clinical and Experimental Metastasis

Volumn 30, Issue 6, 2013, Pages 711-721

  Yang, Xujuan ^a   Belosay, Aashvini ^a   Du, Mengyuan ^a   Fan, Timothy M ^a   Turner, Russell T ^b   Iwaniec, Urszula T ^b   Helferich, William G ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

4T1 cells; ER negative breast cancer; Estradiol; Metastasis

Indexed keywords

ESTRADIOL; FULVESTRANT; KI 67 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CANCER SIZE; CELL MOTILITY; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; ESTROGEN NEGATIVE BREAST CANCER; FEMALE; IN VITRO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; TUMOR INVASION; WESTERN BLOTTING;

ANIMALS; CELL MOVEMENT; ESTRADIOL; FEMALE; KI-67 ANTIGEN; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; RECEPTORS, ESTROGEN;

EID: 84887058893     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9559-0     Document Type: Article

References (68)

1. Jemal A et al (2008) Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100(23):1672-1694
2. Hagemeister FB Jr et al (1980) Causes of death in breast cancer: a clinicopathologic study. Cancer 46(1):162-167
3. Jemal A et al (2003) Cancer statistics, 2003. CA Cancer J Clin 53(1):5-26
4. Pavese JM, Farmer RL, Bergan RC (2010) Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev 29(3):465-482
5. Rosen PR et al (1989) A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 7(3):355-366
6. Lee YT (1985) Patterns of metastasis and natural courses of breast carcinoma. Cancer Metastasis Rev 4(2):153-172
7. Horwitz KB (2008) The year in basic science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk. Mol Endocrinol 22(12):2743-2750
8. Ma H et al (2006) Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 8(4):R43
9. Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344(4):276-285
10. Kaaks R et al (2005) Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12(4):1071-1082
11. Diaz LK, Sneige N (2005) Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 12(1):10-19
12. Skliris GP et al (2008) Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol 109(1-2):1-10
13. Fox EM, Davis RJ, Shupnik MA (2008) ERbeta in breast cancer-onlooker, passive player, or active protector? Steroids 73(11):1039-1051
14. Omoto Y et al (2003) Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 22(32):5011-5020
15. Buteau-Lozano H et al (2002) Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res 62(17):4977-4984
16. Chang EC et al (2006) Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147(10):4831-4842
17. Matthews J et al (2006) Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol 20(3):534-543
18. Roger P et al (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61(6):2537-2541
19. Leygue E et al (1998) Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res 58(15):3197-3201
20. Jarvinen TA et al (2000) Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 156(1):29-35
21. Fuqua SA et al (2003) Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 63(10):2434-2439
22. O'Neill PA et al (2004) Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer 91(9):1694-1702
23. Platet N et al (2004) Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51(1):55-67
24. Neven P et al (2002) Endocrine treatment and prevention of breast and gynaecological cancers. Eur J Cancer 38(Suppl 6):S1-S11
25. Vergote I et al (2000) The oestrogen receptor and its selective modulators in gynaecological and breast cancer. Eur J Cancer 36(Suppl 4):S1-S9
26. Hartman J, Strom A, Gustafsson JA (2009) Estrogen receptor beta in breast cancer-diagnostic and therapeutic implications. Steroids 74(8):635-641
27. Warner M, Gustafsson JA (2010) The role of estrogen receptor beta (ERbeta) in malignant diseases-a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun 396(1):63-66
28. Yue W et al (2010) Effects of estrogen on breast cancer development: role of estrogen receptor independent mechanisms. Int J Cancer 127(8):1748-1757
29. Acconcia F, Kumar R (2006) Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett 238(1):1-14
30. Bjornstrom L, Sjoberg M (2005) Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19(4):833-842
31. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(8784):1-15
32. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(8785):71-85
33. Gupta PB et al (2007) Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res 67(5):2062-2071
34. Banka CL et al (2006) Estrogen induces lung metastasis through a host compartment-specific response. Cancer Res 66(7):3667-3672
35. Reeves PG, Nielsen FH, Fahey GC Jr (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123(11):1939-1951
36. Miller FR (1983) Tumor subpopulation interactions in metastasis. Invasion Metastasis 3(4):234-242
37. Miller FR, Miller BE, Heppner GH (1983) Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 3(1):22-31
38. Hong X et al (2009) EBAG9 inducing hyporesponsiveness of T cells promotes tumor growth and metastasis in 4T1 murine mammary carcinoma. Cancer Sci 100(5):961-969
39. Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52(6):1399-1405
40. Pulaski BA, Ostrand-Rosenberg S (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58(7):1486-1493
41. Pulaski, B.A. and S. Ostrand-Rosenberg, Mouse 4T1 breast tumor model. Curr Protoc Immunol, 2001. Chapter 20: p. Unit-Uni2
42. Adams LS et al (2010) Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway. Cancer Res 70(9):3594-3605
43. Valster A et al (2005) Cell migration and invasion assays. Methods 37(2):208-215
44. Ju YH et al (2001) Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr 131(11):2957-2962
45. Ju YH et al (2006) Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis 27(6):1292-1299
46. Hiraga T et al (2004) Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10(13):4559-4567
47. Muller A et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50-56
48. Ju YH et al (2006) Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice. Carcinogenesis 27(4):856-863
49. Pike MC et al (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15(1):17-35
50. Gottardis MM, Robinson SP, Jordan VC (1988) Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 30(1-6):311-314
51. Alliende ME (2002) Mean versus individual hormonal profiles in the menstrual cycle. Fertil Steril 78(1):90-95
52. Kaaks R et al (2005) Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97(10):755-765
53. Bockhorn M, Jain RK, Munn LL (2007) Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol 8(5):444-448
54. Nogawa M et al (2005) Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett 217(2):243-253
55. Uneda S et al (2009) Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 125(6):1446-1453
56. Oviedo PJ et al (2011) Estradiol induces endothelial cell migration and proliferation through estrogen receptor-enhanced RhoA/ROCK pathway. Mol Cell Endocrinol 335(2):96-103
57. Acconcia F, Barnes CJ, Kumar R (2006) Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology 147(3):1203-1212
58. Sanchez AM et al (2010) Estrogen receptor-alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol 24(11):2114-2125
59. Kedrin D et al (2007) Cell motility and cytoskeletal regulation in invasion and metastasis. J Mammary Gland Biol Neoplasia 12(2-3):143-152
60. Giretti MS et al (2008) Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS ONE 3(5):e2238
61. Zheng S et al (2011) 17beta-Estradiol enhances breast cancer cell motility and invasion via extra-nuclear activation of actin-binding protein ezrin. PLoS ONE 6(7):e22439
62. Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89(17):1260-1270
63. Nilsson UW, Garvin S, Dabrosin C (2007) MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat 102(3):253-261
64. Migliaccio A et al (1996) Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15(6):1292-1300
65. Zhang Z et al (2004) The role of adapter protein Shc in estrogen non-genomic action. Steroids 69(8-9):523-529
66. Song RX et al (2004) The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A 101(7):2076-2081
67. Yang Z, Barnes CJ, Kumar R (2004) Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 10(11):3621-3628
68. Restall C et al (2009) A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth. Int J Cancer 125(2):483-487